Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates

分组1 - Ultragenyx reported a quarterly loss of $1.40 per share, better than the Zacks Consensus Estimate of a loss of $1.45, and an improvement from a loss of $2.23 per share a year ago, resulting in an earnings surprise of 3.45% [1] - The company achieved revenues of $139.49 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 4.04%, and showing a significant increase from $98.05 million in the same quarter last year [2] - Over the last four quarters, Ultragenyx has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] 分组2 - The stock has gained approximately 6.8% since the beginning of the year, while the S&P 500 has increased by 19.8%, indicating underperformance relative to the broader market [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is -$1.25 on revenues of $147.36 million, and for the current fiscal year, it is -$6.29 on revenues of $537.3 million [7] 分组3 - The Zacks Industry Rank places the Medical - Biomedical and Genetics sector in the top 38% of over 250 Zacks industries, suggesting a favorable outlook for stocks within this industry [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]